Sorafenib and entecavir: The dioscuri of treatment for advanced hepatocellular carcinoma?

World Journal of Gastroenterology

Volumn 19, Issue 14, 2013, Pages 2141-2143

  D'Angelo, Salvatore ^a   Secondulfo, Mario ^a   De Cristofano, Raffaele ^a   Sorrentino, Paolo ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

Entecavir; Hepatitis B virus; Hepatocellular carcinoma; Liver function; Sorafenib; Virus

Indexed keywords

ENTECAVIR; SORAFENIB; VIRUS DNA;

ADULT; AGED; CLINICAL ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG EFFICACY; EDITORIAL; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MALE; OVERALL SURVIVAL; TREATMENT OUTCOME; VIRAL CLEARANCE;

EID: 84876352378     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i14.2141     Document Type: Editorial

References (22)

1. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004; 38: S158-S168 [PMID: 15602165 DOI: 10.1097/00004836-200411003-00008]
2. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129 [PMID: 15014185]
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108 [PMID: 15761078]
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]
5. Ikai I, Arii S, Ichida T, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, Yamaoka Y. Report of the 16th follow-up survey of primary liver cancer. Hepatol Res 2005; 32: 163-172 [PMID: 16024288 DOI: 10.1016/ j.hepres.2005.04.005]
6. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750 [PMID: 10072408]
7. Franceschi S, Montella M, Polesel J, La Vecchia C, Crispo A, Dal Maso L, Casarin P, Izzo F, Tommasi LG, Chemin I, Trépo C, Crovatto M, Talamini R. Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev 2006; 15: 683-689 [PMID: 16614109 DOI: 10.1158/1055-9965.EPI-05-0702]
8. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-S50 [PMID: 15508101 DOI: 10.1053/ j.gastro.2004.09.014]
9. Lim SG, Mohammed R, Yuen MF, Kao JH. Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol 2009; 24: 1352-1357 [PMID: 19702903 DOI: 10.1111/j.1440-1746.2009.05985.x]
10. Michielsen P, Ho E. Viral hepatitis B and hepatocellular carcinoma. Acta Gastroenterol Belg 2011; 74: 4-8 [PMID: 21563647]
11. Hino O, Kajino K. Hepatitis virus-related hepatocarcinogenesis. Intervirology 1994; 37: 133-135 [PMID: 7814242]
12. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
13. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917 [DOI: 10.1016/S0140-6736(03)14964-1]
14. Ling-lin Z, Li M, Jin-hui T, Ke-hu Y. Sorafenib for advanced hepatocellular carcinoma: a systematic review. Zhongguo Yixue Kexueyuan Xuebao 2011; 33: 51-57 [PMID: 21375938]
15. Bolondi L, Caspary W, Bennouna J, Thomson B, Van Steenbergen W, Degos F, Shan M, Moscovici M, Llovet J, Bruix J. Clinical benefit of sorafenib in hepatitis C patients with hepatocellular carcinoma (HCC): Subgroup analysis of the SHARP trial. Gastrointestinal Cancers Symposium Abstract, 2008: 129
16. Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, Yang TS, Tak WY, Pan H, Yu S, Xu J, Fang F, Zou J, Lentini G, Voliotis D, Kang YK. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer 2012; 48: 1452-1465 [PMID: 22240282 DOI: 10.1016/j.ejca.2011.12.006]
17. Jin YJ, Shim JH, Lee HC, Yoo DJ, Kim KM, Lim YS, Suh DJ. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma. J Gastroenterol Hepatol 2011; 26: 1380-1388 [PMID: 21884247]
18. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176-182 [PMID: 20006394 DOI: 10.1016/j.jhep.2009.11.007]
19. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012; 57: 442-450 [PMID: 22504333 DOI: 10.1016/ j.jhep.2012.02.033]
20. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236 [PMID: 16250051 DOI: 10.1002/hep.20933]
21. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893 [PMID: 20683932 DOI: 10.1002/hep.23785]
22. Hong F, Chou H, Fiel MI, Friedman SL. Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo. Dig Dis Sci 2013; 58: 257-264 [PMID: 22918681]